Search Results - "Shroff, Rachna T"

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline by Shroff, Rachna T, Kennedy, Erin B, Bachini, Melinda, Bekaii-Saab, Tanios, Crane, Christopher, Edeline, Julien, El-Khoueiry, Anthony, Feng, Mary, Katz, Matthew H G, Primrose, John, Soares, Heloisa P, Valle, Juan, Maithel, Shishir K

“…To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. ASCO convened…”
Get full text

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline by Gordan, John D, Kennedy, Erin B, Abou-Alfa, Ghassan K, Beg, Muhammad Shaalan, Brower, Steven T, Gade, Terence P, Goff, Laura, Gupta, Shilpi, Guy, Jennifer, Harris, William P, Iyer, Renuka, Jaiyesimi, Ishmael, Jhawer, Minaxi, Karippot, Asha, Kaseb, Ahmed O, Kelley, R Kate, Knox, Jennifer J, Kortmansky, Jeremy, Leaf, Andrea, Remak, William M, Shroff, Rachna T, Sohal, Davendra P S, Taddei, Tamar H, Venepalli, Neeta K, Wilson, Andrea, Zhu, Andrew X, Rose, Michal G

“…To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with advanced hepatocellular carcinoma (HCC). ASCO…”
Get full text

Epidemiologic patterns of biliary tract cancer in the United States: 2001–2015 by Koshiol, Jill, Yu, Binbing, Kabadi, Shaum M, Baria, Katherine, Shroff, Rachna T

“…Abstract Background Biliary tract cancer (BTC) includes intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma, gallbladder cancer, and ampulla…”
Get full text

The immunogenomic landscape of resected intrahepatic cholangiocarcinoma by Carapeto, Fernando, Bozorgui, Behnaz, Shroff, Rachna T., Chagani, Sharmeen, Solis Soto, Luisa, Foo, Wai Chin, Wistuba, Ignacio, Meric‐Bernstam, Funda, Shalaby, Ahmed, Javle, Milind, Korkut, Anil, Kwong, Lawrence N.

“…Background and Aims Cholangiocarcinoma (CCA) is a deadly and highly therapy‐refractory cancer of the bile ducts, with early results from immune checkpoint…”
Get full text

New Treatment Options for Advanced Biliary Tract Cancer by Mizrahi, Jonathan D., Shroff, Rachna T.

“…Opinion statement The standard of care first-line therapy for patients with advanced biliary tract cancers eligible for treatment continues to be the…”
Get full text

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial by Makawita, Shalini, K Abou-Alfa, Ghassan, Roychowdhury, Sameek, Sadeghi, Saeed, Borbath, Ivan, Goyal, Lipika, Cohn, Allen, Lamarca, Angela, Oh, Do-Youn, Macarulla, Teresa, T Shroff, Rachna, Howland, Michael, Li, Ai, Cho, Terry, Pande, Amit, Javle, Milind

“…Cholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately 15% of intrahepatic cholangiocarcinomas contain FGFR alterations…”
Get full text

Overall Survival and Clinical Characteristics of BRCA‐Associated Cholangiocarcinoma: A Multicenter Retrospective Study by Golan, Talia, Raitses‐Gurevich, Maria, Kelley, Robin K., Bocobo, Andrea G., Borgida, Ayelet, Shroff, Rachna T., Holter, Spring, Gallinger, Steven, Ahn, Daniel H., Aderka, Dan, Apurva, Jain, Bekaii‐Saab, Tanois, Friedman, Eitan, Javle, Milind

“…Background Biliary tract malignancies, in particular cholangiocarcinomas (CCA), are rare tumors that carry a poor prognosis. BRCA2 mutation carriers have an…”
Get full text

What is the role of PARP inhibitors in pancreatic cancer? by Halder, Ritika, Shroff, Rachna T.

Get full text

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience by Cloyd, Jordan M., Katz, Matthew H. G., Prakash, Laura, Varadhachary, Gauri R., Wolff, Robert A., Shroff, Rachna T., Javle, Milind, Fogelman, David, Overman, Michael, Crane, Christopher H., Koay, Eugene J., Das, Prajnan, Krishnan, Sunil, Minsky, Bruce D., Lee, Jeffrey H., Bhutani, Manoop S., Weston, Brian, Ross, William, Bhosale, Priya, Tamm, Eric P., Wang, Huamin, Maitra, Anirban, Kim, Michael P., Aloia, Thomas A., Vauthey, Jean-Nicholas, Fleming, Jason B., Abbruzzese, James L., Pisters, Peter W. T., Evans, Douglas B., Lee, Jeffrey E.

“…Background The purpose of this study was to evaluate a single-institution experience with delivery of preoperative therapy to patients with pancreatic ductal…”
Get full text

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies by Javle, Milind M, Shroff, Rachna T, Xiong, Henry, Varadhachary, Gauri A, Fogelman, David, Reddy, Shrikanth A, Davis, Darren, Zhang, Yujian, Wolff, Robert A, Abbruzzese, James L

“…The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an…”
Get full text

Next‐generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance by Ahn, Daniel H., Javle, Milind, Ahn, Chul W., Jain, Apurva, Mikhail, Sameh, Noonan, Anne M., Wu, Christina, Shroff, Rachna T., Chen, James L., Bekaii‐Saab, Tanios

“…BACKGROUND Biliary tract cancers (BTCs) are uncommon and are associated with a dismal prognosis. Combinations of gemcitabine and platinum chemotherapy…”
Get full text

Molecular characterization of gallbladder cancer using somatic mutation profiling by Javle, Milind, MD, Rashid, Asif, MD, PhD, Churi, Chaitanya, MBBS, Kar, Siddhartha, MBBS, MPH, Zuo, Mingxin, PhD, Eterovic, Agda Karina, PhD, Nogueras-Gonzalez, Graciela M., MPH, Janku, Filip, MD, PhD, Shroff, Rachna T., MD, Aloia, Thomas A., MD, Vauthey, Jean-Nicholas, MD, Curley, Steven, MD, Mills, Gordon, MD, PhD, Roa, Ivan, MD

“…Summary Gallbladder cancer is relatively uncommon, with a high incidence in certain geographic locations, including Latin America, East and South Asia, and…”
Get full text

Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma by Cloyd, Jordan M., Crane, Christopher H., Koay, Eugene J., Das, Prajnan, Krishnan, Sunil, Prakash, Laura, Snyder, Rebecca A., Varadhachary, Gauri R., Wolff, Robert A., Javle, Milind, Shroff, Rachna T., Fogelman, David, Overman, Michael, Wang, Huamin, Maitra, Anirban, Lee, Jeffrey E., Fleming, Jason B., Katz, Matthew H. G.

“…BACKGROUND Previous studies have suggested that preoperative chemoradiation (CRT) is associated with an improved margin‐negative resection rate among patients…”
Get full text

Pancreatic cancer by Mizrahi, Jonathan D, Surana, Rishi, Valle, Juan W, Shroff, Rachna T

“…Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10% in the USA, and it is becoming an increasingly common cause of…”
Get full text

Underuse of surgical resection among elderly patients with early-stage pancreatic cancer by He, Weiguo, PhD, Zhao, Hui, PhD, Chan, Wenyaw, PhD, Lopez, David, DrPH, Shroff, Rachna T., MD, Giordano, Sharon H., MD

“…Background Although surgery improves the health care quality and outcomes of patients with early-stage pancreatic cancer, these patients' operative resection…”
Get full text

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma by Abdel-Wahab, Reham, Varadhachary, Gauri R, Bhosale, Priya R, Wang, Xuemei, Fogelman, David R, Shroff, Rachna T, Overman, Michael J, Wolff, Robert A, Javle, Milind

“…Binding of insulin-like growth factor-I (IGF-1) to its receptor (IGF-1R) initiates downstream signals that activate PI3K/Akt/mTOR and MEK/Erk pathways, which…”
Get full text

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures by Mody, Kabir, Jain, Prerna, El-Refai, Sherif M, Azad, Nilofer S, Zabransky, Daniel J, Baretti, Marina, Shroff, Rachna T, Kelley, R Katie, El-Khouiery, Anthony B, Hockenberry, Adam J, Lau, Denise, Lesinski, Gregory B, Yarchoan, Mark

“…Biliary tract cancers (BTCs) are aggressive cancers that carry a poor prognosis. An enhanced understanding of the immune landscape of anatomically and…”
Get more information

Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy by Rogers, Jane E, Bolonesi, Ryan M, Rashid, Asif, Elsayes, Khaled M, Elbanan, Mohamed G, Law, Lindsey, Kaseb, Ahmed, Shroff, Rachna T

“…Combined hepatocellular-cholangiocarcinoma (HCC-CC) has a reported incidence of less than 5% of primary hepatic malignancies. The treatment approach to this…”
Get full text

Precision Medicine in Biliary Tract Cancer by Scott, Aaron J., Sharman, Reya, Shroff, Rachna T.

“…Precision medicine has become a dominant theme in the treatment of biliary tract cancers (BTCs). Although prognosis remains poor, technologies for improved…”
Get full text

Current and emerging therapies for advanced biliary tract cancers by Kam, Audrey E, Masood, Ashiq, Shroff, Rachna T

“…Biliary tract cancers (cholangiocarcinomas and gallbladder cancers) are increasing in incidence and have a poor prognosis. Most patients present with advanced…”
Get more information